Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gavin P Reynolds

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
Pharmacogenomics|September 12, 2002
Weight gain, antipsychotic drug treatment and pharmacogenomicsGavin P Reynolds
Journal of Clinical Psychopharmacology|June 10, 2025
Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for SchizophreniaGavin P Reynolds
Therapeutic Advances in Psychopharmacology|August 29, 2013
Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapineGavin P Reynolds
Handbook of Experimental Pharmacology|November 7, 2012
The pharmacogenetics of antipsychotic treatmentGavin P Reynolds
Journal of Affective Disorders|August 14, 2025
Air pollution and psychiatric outcomes - is Mendelian randomisation an appropriate analysis?Gavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|April 24, 2024
The trace amine-associated receptor 1 agonists - non-dopaminergic antipsychotics or covert modulators of D2 receptors?Gavin P Reynolds
Epigenomics|May 4, 2021
Early life trauma, DNA methylation and mental illnessGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|September 11, 2004
Receptor mechanisms in the treatment of schizophreniaGavin P Reynolds
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|February 23, 2013
Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical ReviewGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|July 14, 2021
High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?Gavin P Reynolds
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
Pharmacogenomics|September 12, 2002
Weight gain, antipsychotic drug treatment and pharmacogenomicsGavin P Reynolds
Journal of Clinical Psychopharmacology|June 10, 2025
Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for SchizophreniaGavin P Reynolds
Therapeutic Advances in Psychopharmacology|August 29, 2013
Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapineGavin P Reynolds
Handbook of Experimental Pharmacology|November 7, 2012
The pharmacogenetics of antipsychotic treatmentGavin P Reynolds
Journal of Affective Disorders|August 14, 2025
Air pollution and psychiatric outcomes - is Mendelian randomisation an appropriate analysis?Gavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|April 24, 2024
The trace amine-associated receptor 1 agonists - non-dopaminergic antipsychotics or covert modulators of D2 receptors?Gavin P Reynolds
Epigenomics|May 4, 2021
Early life trauma, DNA methylation and mental illnessGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|September 11, 2004
Receptor mechanisms in the treatment of schizophreniaGavin P Reynolds
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|February 23, 2013
Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical ReviewGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|July 14, 2021
High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?Gavin P Reynolds
Pageof 14